Medanta Share Price: Q4 Results Mein Jabardast Growth, Par Valuation Ki Chinta!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Medanta Share Price: Q4 Results Mein Jabardast Growth, Par Valuation Ki Chinta!
Overview

Global Health Ltd (Medanta) ne FY26 ke Q4 mein kamaal kar dikhaya! Company ka revenue **25%** jump kar **₹1,159 Crore** ho gaya aur profit toh **42%** badh kar **₹144 Crore** tak pahunch gaya. Sab numbers mast hain, but investors ko valuation ko lekar thodi fikar ho rahi hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Lo bhai, Medanta (Global Health Ltd) ne FY26 ka Q4 results announce kiya hai aur numbers toh ekdum mast hain! Revenue 25% bdhakr ₹1,159 Crore ho gaya aur net profit toh 42% tez ho gaya, sidha ₹144 Crore pe pahunch gaya. Matlab 12.4% ka profit margin, kya baat hai!

Company apne expansion plans pe bhi zordaar kaam kar rahi hai. Agle 3-4 saal mein ye log 2,700 naye beds add karne wale hain 5 naye projects ke through. Haan, jo Noida wala hospital hai na, woh abhi thoda loss mein hai, Q4 mein ₹23.6 Crore ka EBITDA loss tha. Lekin management keh raha hai ki H2 FY27 tak yeh breakeven kar lega. Yeh ek badi news hai unke liye. Baaki purane hospitals jo Gurugram, Indore aur Ranchi mein hain, unka revenue 9% badha hai aur margins 24.4% stable hain.

Abhi tak sab accha lag raha hai, lekin asli khel yahi hai - valuation ka. Medanta ka share price abhi 54-64 times earnings pe trade kar raha hai. Ye Indian healthcare industry ke average 40x se kaafi upar hai. Agar Apollo Hospitals (jo lagbhag 63.87x pe hai) aur Fortis Healthcare (jo 75x pe hai) se compare karein toh valuation similar lagta hai, par Medanta ki projected growth next 2 saal ke liye sirf 12% hai, jabki industry 20% grow karne wali hai. Toh yahan investors ko thoda sawaal uth raha hai ki kya itne mehenge stock ko khareedna chahiye?

Risks toh hain hi yaar. Noida hospital ko time pe breakeven karna, expansion plans ko manage karna jismein bahut paisa lagega, aur Apollo, Fortis jaise competitors se competition. Plus, government regulations ka bhi threat rehta hai. Analysts average target ₹1,309.99 de rahe hain, jo current price se sirf 4% upar hai. Toh overall, growth drivers toh hain, par valuation aur execution pe nazar rakhni padegi.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.